Tempest Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Tempest Therapeutics

20/03/2024 12:00

* Tempest Therapeutics Inc  TPST.OQ  reported a quarterly
adjusted
loss of 38 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -63 cents.  The mean expectation of
five analysts for the quarter was for a loss of 39 cents per
share. Wall Street expected results to range from -43 cents
to -32 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Tempest Therapeutics Inc's reported EPS for the quarter
was a
loss of 38 cents​.
    * The company reported a quarterly loss of $7.49 million.
    * Tempest Therapeutics Inc shares had fallen by 15.0% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $13.00 
This summary was machine generated from LSEG data March 20 at
11:59 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.39          -0.38          Beat
 Sep. 30 2023      -0.57          -0.48          Beat
 Jun. 30 2023      -0.52          -0.54          Missed
 Mar. 31 2023      -0.64          -0.55          Beat